Study identifier:D3780C00005
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Randomised, Double-Blind, Placebo-Controlled, Single-Centre Study to Determine the Effect of Intradermal AZD3161 on Quantitative Sensory Testing Variables in Normal and UVC Exposed Skin in Healthy Volunteers
Peripheral neuropathic pain
Phase 1
Yes
AZD3161, Lidocaine, AZD3161 Placebo
All
26
Interventional
18 Years - 55 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verified 01 Apr 2011 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 150 μL intradermal injection of 1 μmol/L AZD3161 | Drug: AZD3161 Single dose, intradermal injection |
Experimental: 2 150 μL intradermal injection of 6 μmol/L AZD3161 | Drug: AZD3161 Single dose, intradermal injection |
Experimental: 3 150 μL intradermal injection of 30 μmol/L AZD3161 | Drug: AZD3161 Single dose, intradermal injection |
Active Comparator: 4 150 μL intradermal injection of 10 mg/mL Lidocaine | Drug: Lidocaine Single dose, intradermal injection |
Placebo Comparator: 5 150 μL intradermal injection of AZD3161 placebo | - |